AUPH May 2024 6.000 put
- Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.
- Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 09, 2024--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
- Zacks
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
